Table 2.
Patients' outcome (n = 121).
| Parameter |
Median, months |
95% CI | Log-rank p-value |
|---|---|---|---|
| Follow-up | 39.5 | 32.1–77.7 | |
| OS | 48.0 | 12.9–83.0 | |
| OS no BMs | 72.4 | 33.0–111.7 | 0.323 |
| OS BMs | 34.8 | NA | |
| Brain RT | NR | NA | 0.567a |
| No brain RT | 24.6 | 20.2–29.0 | |
| 1st line TKI | 35.8 | 16.9–54.7 | 0.526 |
| >1st line TKI | 72.4 | 29.3–115.4 | |
| 1st line TKI | 35.8 | NA | 0.955 |
| 1st line CHT | 48.0 | 11.8–84.1 | |
| One TKI line | 34.8 | 21.6–48,0 | 0.016 |
| >One TKI line | 85.7 | 63.9–107.5 | |
| Use of alectinib/lorlatinib | 85.7 | 64.0–107.5 | 0.022 |
| Use of crizotinib ± ceritinib | 37.3 | 16.1–58.6 |
a
On 37 patients with BM only.
BMs, brain metastases; CHT, chemotherapy; CI, confidence interval; NA, not assessable; NR, not reached; OS, overall survival; RT, radiotherapy; TKI, tyrosine kinase inhibitor.